STOCKWATCH: Will cancer info dump ruffle markets?
This article was originally published in Scrip
The big news at the European Cancer Congress in Amsterdam this weekend was not down to any one particular pharma company's good or bad clinical results. It was simply that all the news from the Congress was released at the same time as the organizers lifted all the embargos on presentations at the meeting. That meant that a bolus of potential market-moving and market-sensitive material was released over the weekend when no trading was taken place, rather than being staggered over the course of the Congress.
You may also be interested in...
A complete response letter from the FDA knocked Intercept’s stock price for six, but perhaps the FDA is sending wider messages about NASH.
Gene and cellular therapies that can replace decades of expensive therapy do not come cheap. Even the initial remedy of payment by installments could be irrelevant when not all patients respond in the same way.
With Lilly, Pfizer and Novartis duking it out for early-stage breast cancer patients, how many drugs for the same indication is too many?